Cover Image
市場調查報告書

完全置換型人工心臟的全球市場:醫療設備的開發平台評估

Total Artificial Heart - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 358225
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
完全置換型人工心臟的全球市場:醫療設備的開發平台評估 Total Artificial Heart - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年05月10日 內容資訊: 英文 54 Pages
簡介

本報告提供全球全人工心臟市場上主要的開發中產品 (醫療設備) 及其臨床實驗的進展調查,再加上產品功能·特性比較分析 (臨床實驗的各進展階段) ,還有主要企業簡介及代表性產品,彙整近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 完全置換型人工心臟概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • 完全置換型人工心臟的企業:各臨床實驗階段的開發中產品
  • 完全置換型人工心臟:各臨床實驗階段的開發中產品

第5章 完全置換型人工心臟市場:企業·產品概要

  • Abiomed, Inc.
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart, Inc.
  • Foster-Miller, Inc. (Inactive)
  • MicroMed Cardiovascular, Inc.
  • SynCardia Systems, Inc.
  • 東京大學

第6章 完全置換型人工心臟市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's Medical Devices sector report, "Total Artificial Heart - Medical Devices Pipeline Assessment, 2017" provides an overview of Total Artificial Heart currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Total Artificial Heart Overview 6

3 Products under Development 7

  • 3.1 Total Artificial Heart - Pipeline Products by Stage of Development 7
  • 3.2 Total Artificial Heart - Pipeline Products by Territory 8
  • 3.3 Total Artificial Heart - Pipeline Products by Regulatory Path 9
  • 3.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
  • 3.5 Total Artificial Heart - Ongoing Clinical Trials 11

4 Total Artificial Heart - Pipeline Products under Development by Companies 12

  • 4.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development 12
  • 4.2 Total Artificial Heart - Pipeline Products by Stage of Development 13

5 Total Artificial Heart Companies and Product Overview 14

  • 5.1 Abiomed Inc Company Overview 14
    • 5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 BiVacor Pty Ltd Company Overview 16
    • 5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.3 Carmat SAS Company Overview 17
    • 5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.4 Cleveland Heart Inc Company Overview 20
    • 5.4.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.5 Foster-Miller, Inc. (Inactive) Company Overview 21
    • 5.5.1 Foster-Miller, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.6 Indian Institute of Technology Delhi Company Overview 22
    • 5.6.1 Indian Institute of Technology Delhi Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.7 ReliantHeart, Inc. Company Overview 23
    • 5.7.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.8 SynCardia Systems, Inc. Company Overview 24
    • 5.8.1 SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.9 The University of Tokyo Company Overview 30
    • 5.9.1 The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 30

6 Total Artificial Heart- Recent Developments 31

  • 6.1 May 04, 2017: Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year 31
  • 6.2 May 02, 2017: CARMAT announces the resumption of the PIVOTAL study in France 32
  • 6.3 Apr 19, 2017: Turkish Man Becomes World's Longest Supported Total Artificial Heart Patient 32
  • 6.4 Mar 14, 2017: SynCardia Names New VP of Manufacturing and Facilities 33
  • 6.5 Feb 06, 2017: CARMAT provides an update regarding the suspended PIVOTAL study on its bioprosthetic artificial heart 34
  • 6.6 Jan 26, 2017: Abiomed Announces Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year 34
  • 6.7 Jan 25, 2017: Two Cardiology Experts Join CARMAT's Board of Directors as Independent Members 35
  • 6.8 Jan 09, 2017: Abiomed Announces Preliminary Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year 36
  • 6.9 Jan 04, 2017: Clinica Universidad de Navarra Implants Spain's First SynCardia Total Artificial Heart 37
  • 6.10 Nov 30, 2016: Update on the PIVOTAL study on the CARMAT bioprosthetic artificial heart 38
  • 6.11 Nov 09, 2016: Arrhythmia Research Technology Reports 2016 Third Quarter Results 38
  • 6.12 Oct 27, 2016: Abiomed Announces Q2 FY 2017 Revenue of $103 Million, Up 35% Over Prior Year 40
  • 6.13 Oct 27, 2016: Amedisys Previews Third Quarter 2016 Results 41
  • 6.14 Oct 04, 2016: EKN Duisburg Becomes First Device-Only Center to Reach 50 SynCardia Artificial Heart Implants 41
  • 6.15 Sep 08, 2016: CARMAT: 2016 half-year results in line with the progress achieved by the Company 42
  • 6.16 Sep 01, 2016: CARMAT announces the departure of Marcello Conviti, CEO 43
  • 6.17 Sep 01, 2016: Stephane Piat, Previously Division Vice President of Abbott in California, Has Been Appointed CEO of CARMAT 43
  • 6.18 Aug 29, 2016: CARMAT Announces the Start of the PIVOTAL Study 44
  • 6.19 Aug 16, 2016: SynCardia Artificial Heart to Emerge from Chapter 11 Reorganization With New Owner on September 16, 2016 45
  • 6.20 Aug 11, 2016: Arrhythmia Research Technology Reports 2016 Second Quarter Results 46
  • 6.21 Jul 28, 2016: Abiomed Announces Q1 FY 2017 Revenue of $103.0 Million, Up 40% Over Prior Year 48
  • 6.22 Jul 13, 2016: CARMAT has obtained the necessary approvals to begin the PIVOTAL study in France 49
  • 6.23 Jun 23, 2016: CARMAT has begun, with DEKRA, the CE certification process for its bioprosthetic artificial heart 49

7 Appendix 51

  • 7.1 Methodology 51
  • 7.2 About GlobalData 54
  • 7.3 Contact Us 54
  • 7.4 Disclaimer 54

List of Tables

1.1 List of Tables

  • Table 1: Total Artificial Heart - Pipeline Products by Stage of Development 7
  • Table 2: Total Artificial Heart - Pipeline Products by Territory 8
  • Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path 9
  • Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
  • Table 5: Total Artificial Heart - Ongoing Clinical Trials 11
  • Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development 12
  • Table 7: Total Artificial Heart - Pipeline Products by Stage of Development 13
  • Table 8: Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview 14
  • Table 9: AbioCor II - Product Status 14
  • Table 10: AbioCor II - Product Description 15
  • Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 12: BiVACOR Device - Product Status 16
  • Table 13: BiVACOR Device - Product Description 16
  • Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 15: Artificial Heart - Product Status 17
  • Table 16: Artificial Heart - Product Description 18
  • Table 17: Carmat SAS - Ongoing Clinical Trials Overview 18
  • Table 18: Artificial Heart - Clinical Evaluation of the Carmat Total Artificial Heart for Patients with Advanced Heart Failure 19
  • Table 19: Artificial Heart - First-in-man CARMAT's Bioprosthetic Heart Trial For End-stage Heart Failure 19
  • Table 20: Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 21: SmartHeart TAH - Product Status 20
  • Table 22: SmartHeart TAH - Product Description 20
  • Table 23: Foster-Miller, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 24: MagScrew Total Artificial Heart - Product Status 21
  • Table 25: MagScrew Total Artificial Heart - Product Description 21
  • Table 26: Indian Institute of Technology Delhi Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 27: Artificial Heart - Product Status 22
  • Table 28: Artificial Heart - Product Description 22
  • Table 29: ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 30: Pulse Less Total Artificial Heart - Product Status 23
  • Table 31: Pulse Less Total Artificial Heart - Product Description 23
  • Table 32: SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 33: 50cc SynCardia Total Artificial Heart - Adults Bridge To Transplant - Product Status 24
  • Table 34: 50cc SynCardia Total Artificial Heart - Adults Bridge To Transplant - Product Description 24
  • Table 35: 50cc SynCardia Total Artificial Heart - Destination Therapy - Product Status 25
  • Table 36: 50cc SynCardia Total Artificial Heart - Destination Therapy - Product Description 25
  • Table 37: 50cc SynCardia Total Artificial Heart - Pediatric Bridge To Transplant - Product Status 25
  • Table 38: 50cc SynCardia Total Artificial Heart - Pediatric Bridge To Transplant - Product Description 26
  • Table 39: 70cc SynCardia Temporary Total Artificial Heart - Destination Therapy - Product Status 26
  • Table 40: 70cc SynCardia Temporary Total Artificial Heart - Destination Therapy - Product Description 27
  • Table 41: SynCardia Systems, Inc. - Ongoing Clinical Trials Overview 27
  • Table 42: 70cc SynCardia Temporary Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT) 28
  • Table 43: 50cc SynCardia Total Artificial Heart - Pediatric Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant 28
  • Table 44: 50cc SynCardia Total Artificial Heart - Adults Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant 29
  • Table 45: The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 46: Helical Flow Total Artificial Heart - Product Status 30
  • Table 47: Helical Flow Total Artificial Heart - Product Description 30
  • Table 48: Glossary 53

List of Figures

1.2 List of Figures

  • Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development 7
  • Figure 2: Total Artificial Heart - Pipeline Products by Territory 8
  • Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path 9
  • Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
  • Figure 5: Total Artificial Heart - Ongoing Clinical Trials 11
Back to Top